Xeris Pharmaceuticals, Inc. (XERS)
| Market Cap | 306.30M |
| Revenue (ttm) | 63.47M |
| Net Income (ttm) | -138.03M |
| Shares Out | 135.53M |
| EPS (ttm) | -1.42 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,540,765 |
| Open | 2.04 |
| Previous Close | 2.00 |
| Day's Range | 2.02 - 2.29 |
| 52-Week Range | 1.25 - 4.98 |
| Beta | 1.81 |
| Analysts | Buy |
| Price Target | 6.38 (+182.3%) |
| Earnings Date | n/a |
About XERS
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's synd...
Financial Performance
In 2021, XERS's revenue was $49.59 million, an increase of 142.67% compared to the previous year's $20.44 million. Losses were -$122.73 million, 34.7% more than in 2020.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for XERS stock is "Buy." The 12-month stock price forecast is 6.38, which is an increase of 182.30% from the latest price.
News
Xeris Announces Full Results From the Logics Study of Recorlev® and Presentation of New Burden of Illness in Cushing'...
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, ...
Xeris Biopharma Reports First Quarter Financial Results and Upcoming Events
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, ...
Xeris Biopharma to Report First Quarter 2022 Financial Results on May 11, 2022
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, ...
Xeris Biopharma Announces Gvoke® Kit Is Now Available for the Treatment of Severe Hypoglycemia in Adults and Children...
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, ...
Xeris Biopharma Reports Fourth Quarter and Full-year 2021 Financial Results and Recent Events
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, ...
Xeris Announces $150M Senior Secured Term Loan Facility With Hayfin Capital
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (“Xeris” or “the Company”) (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in...
Xeris Biopharma to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, ...
Xeris Biopharma (XERS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
Xeris Biopharma (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Xeris Biopharma to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and ga...
Xeris Biopharma Announces Recorlev® (levoketoconazole) Is Now Commercially Available for the Treatment of Endogenous ...
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, ...
Xeris Biopharma Eyes High End Of FY21 Sales Outlook
Xeris Biopharma Holdings Inc (NASDAQ: XERS) has reaffirmed its preliminary 2021 pro forma sales at a high-end of $76 million - $80 million guidance, approximately 55% growth from 2020. The company held ...
Xeris Biopharma Reaffirms 2021 Guidance and Provides Business Update
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) (“Xeris” or the “Company”), a biopharmaceutical company developing and commercializing unique therapies for patient populations in...
PANTHERx Rare Selected By Xeris Pharmaceuticals To Distribute Recorlev
PANTHERx Rare announces that it has been selected by Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Xeris Biopharma Holdings, Inc., as the exclusive U.S. pharmacy distribution partner for a n...
PANTHERx Rare® Selected by Xeris Pharmaceuticals to Distribute Recorlev® (levoketoconazole) for the treatment of endo...
PITTSBURGH, Jan. 13, 2022 /PRNewswire/ -- PANTHERx Rare announces that it has been selected by Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Xeris Biopharma Holdings, Inc., as the exclusive ...
Xeris Biopharma to Participate in H.C. Wainwright BioConnect 2022 Virtual Conference
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and ga...
Xeris Biopharma Enters Into Agreement for $30 Million Private Placement
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) (“Xeris” or the “Company”), a biopharmaceutical company developing and commercializing unique therapies for patient populations in...
Moderna's on the Rise, but This Small Biotech Is the Nasdaq's Big Winner on New Year's Eve
Find out what's moving markets on the last day of the year.
Here's Why Xeris Biopharma Stock Is Jumping Today
The FDA approved Recorlev for the treatment of endogenous Cushing's syndrome.
XERS Stock Pops on Huge FDA News. Here's What to Know.
The FDA approved Xeris' Recorlev drug for certain adult patients with Cushing's syndrome, sending XERS stock higher. The post XERS Stock Pops on Huge FDA News.
Why Xeris Biopharma Shares Are Rising Today
Xeris Biopharma Holdings Inc (NASDAQ: XERS) is trading higher Friday morning after the company announced U.S. Food and Drug Administration approval of Recorlev for the treatment of endogenous hypercorti...
Xeris Biopharma soars on premarket leading volume after FDA approval of Cushing's syndrome treatment
Shares of Xeris Biopharma Holdings Inc. XERS, -3.19% shot up 24.3% on heavy volume in premarket trading Friday toward a five-month high, after the biopharmaceutical company said its Recorlev has been ap...
Xeris Biopharma Announces U.S. FDA Approval of Recorlev® (levoketoconazole) for the Treatment of Endogenous Hypercort...
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, ...
5 Beaten Down Biotech Stocks That Could Bounce Big In 2022
Biotech stocks remain poised to eke out modest gains for 2021 after the stellar gains of the previous year. COVID-19 drug and vaccine developers experienced volatility throughout 2021 amid delays in pro...
Xeris Biopharma Announces the Availability of Ogluo® in the UK Through Its Commercialization Partner, Tetris Pharma
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, ...
4 Penny Stocks To Buy For Under $5 Before 2022
You can buy these penny stocks for under $5 but are they worth the risk? The post 4 Penny Stocks To Buy For Under $5 Before 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | Penn...